Indivior has dosed the first subject in a Phase II clinical trial of INDV-2000 for individuals with opioid use disorder (OUD).
The double-blind, placebo-controlled, randomised, dose-ranging study aims to evaluate the safety and efficacy of the asset over a three-month period in treatment-seeking participants with moderate to severe OUD.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It will enrol individuals who have recently initiated or completed short-term medically supervised opioid withdrawal using transmucosal (TM) buprenorphine and are considering a non-opioid treatment alternative.
On the first day, participants will be randomised to receive either INDV-2000 or a placebo alongside TM buprenorphine until day seven.
Following this, INDV-2000 or a placebo will be administered independently from day eight onwards.
The randomised treatment period will last for three months or until the participant’s final study visit.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe treatment period may also conclude if a participant requires buprenorphine rescue therapy due to a relapse into illicit opioid use.
INDV-2000, an oral orexin-1 receptor (OX1R) antagonist, has shown promising results in rodent models of addiction and has a safety profile that is suitable for human clinical trials.
This study is supported by a grant under the NIH-HEAL initiative, which is dedicated to the clinical development of new treatments for addiction.
Indivior chief scientific officer Christian Heidbreder said: “INDV-2000 provides Indivior with a unique opportunity to further address unmet patient needs in the treatment of OUD, with potentially the first non-opioid orexin-targeted therapy.
“By providing a potential therapeutic option for patients who might benefit from a non-opioid alternative, INDV-2000 may broaden the spectrum of care for OUD treatment.
“This milestone highlights Indivior’s commitment to developing a wider range of therapeutics in both the opioid and non-opioid treatment category, ultimately providing more choices for the patient.”
